FDA Grants Emergency Authorization for BECTON’s Mpox Virus Test
January 17, 2023
Trending News 🌧️
Becton ($NYSE:BDX), Dickinson and Company, commonly known as BD, is a medical technology company offering products, services, and solutions for the healthcare industry. Recently, the U.S. Food and Drug Administration granted emergency authorization to BD and CerTest Biotec’s molecular polymerase chain reaction test for detecting the Mpox virus. This provides an easier and faster way to diagnose the virus, as well as reduce the risk of false negatives. The Mpox virus is a contagious virus that can cause severe respiratory illnesses, including pneumonia. It is particularly dangerous for infants and young children, who are more susceptible to its effects. The test’s authorization will help healthcare providers diagnose the virus more quickly, allowing them to begin treatment promptly. This is especially important when it comes to Mpox virus, as early diagnosis and treatment are essential for preventing serious complications.
Additionally, this authorization can help reduce the burden on health systems and hospitals already facing a shortage of resources. The emergency use authorization from the FDA is an important step forward in identifying and treating Mpox virus. It will help healthcare providers diagnose the virus faster and more accurately, allowing for better patient outcomes. This is an important development for both BD and CerTest Biotec, as it expands their portfolio of products and services for the healthcare industry.
Price History
The news of the FDA granting emergency authorization to BECTON‘s Mpox Virus Test has largely been met with negative sentiment. On Monday, BECTON stock opened at $260.0 and closed at $252.4, down 2.7% from its prior closing price of $259.3. This news has been met with mixed reactions, as some investors were expecting greater gains due to the FDA approval. The Mpox Virus Test is a diagnostic tool that can detect the Mpox virus in a patient’s blood or saliva sample. This will allow medical professionals to quickly diagnose and treat patients who may have the virus. BECTON’s test has been approved under the FDA’s Emergency Use Authorization (EUA), which allows the use of medical products that have not yet been approved for use by the FDA.
The news of the FDA’s approval has been largely viewed as a positive for BECTON, as it will allow them to market and sell their test to medical professionals. The EUA also allows for BECTON to be reimbursed by Medicare and Medicaid for the tests they provide, which will help increase their revenue. Although the news of the FDA’s approval is largely positive for BECTON, investors were expecting greater gains due to the announcement. Investors are cautious about investing in the stock with the current negative sentiment surrounding the news and continue to watch the stock closely. It will be interesting to see if the stock can rebound from the initial dip in price or if the negative sentiment will continue to weigh on the stock for weeks to come. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Becton. More…
| Total Revenues | Net Income | Net Margin |
| 18.87k | 1.69k | 11.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Becton. More…
| Operations | Investing | Financing |
| 2.61k | -1.88k | -3.31k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Becton. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 53.2k | 27.7k | 89.39 |
Key Ratios Snapshot
Some of the financial key ratios for Becton are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 3.0% | 3.4% | 13.4% |
| FCF Margin | ROE | ROA |
| 7.8% | 5.3% | 2.6% |
VI Analysis
BECTON’s fundamentals are indicative of its long term potential as evidenced by the VI App. Their star chart indicates a high health score of 8/10, thanks to its positive cashflows and moderate debt load. BECTON is classified as an “elephant”, a company that has a large amount of assets relative to its liabilities. Investors who prefer such companies will likely be interested in BECTON. In terms of other metrics, BECTON is strong in its assets, profitability and medium in growth. However, its dividend yield is relatively weak. Given its strong fundamentals, BECTON is well-positioned to weather any crisis without the risk of bankruptcy. Furthermore, its moderate debt load indicates that any cash flow-related issues can be addressed without too much difficulty. Overall, BECTON is an attractive option for investors who are looking for a company with a solid financial outlook. Its assets and profitability make it an attractive option for investors who are looking for a long term investment. In addition to its strong fundamentals, BECTON’s moderate debt load suggests that any cash flow-related issues can be addressed without too much difficulty. More…
VI Peers
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.
– Penumbra Inc ($NYSE:PEN)
Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.
Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.
The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.
– Teleflex Inc ($NYSE:TFX)
Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.
– SheerVision Inc ($OTCPK:SVSO)
SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.
Summary
The recent news of the U.S. Food and Drug Administration (FDA) granting emergency authorization for BECTON‘s mPOX virus test has been met with mostly negative sentiment from investors. Despite this, investors may still be interested in investing in BECTON for its potential for growth. The company is well-known for its leadership in the medical device industry and has a strong record of innovation. BECTON has a broad range of products and services, including medical diagnostics, laboratory equipment, and medical supplies.
Additionally, the company is financially sound, with a strong balance sheet and long-term debt management. With the addition of the new virus test, BECTON may be poised to benefit from increased demand. For investors looking to gain exposure to this dynamic industry, BECTON is a viable option worth considering.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
